LFA
ACAD icon

Legacy Financial Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Legacy Financial Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-111
Closed -$3K – 119
2019
Q1 		$3K Buy
+111
New +$2.59K ﹤0.01% 838

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Legacy Financial Advisors's ACAD Position: Q2 2019 in Review

Legacy Financial Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2019, closing a stake of 111 shares — an estimated $3K sold.

Legacy Financial Advisors first reported a position in ACAD in Q1 2019 and held it in 1 quarter. The position peaked at $3K in Q1 2019. 196 funds tracked by Wall St. Rank hold ACAD as of Q2 2019.

  • Legacy Financial Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Legacy Financial Advisors sold 111 Acadia Pharmaceuticals shares in Q2 2019, an estimated $3K.
  • Legacy Financial Advisors first reported a position in Acadia Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Legacy Financial Advisors's Acadia Pharmaceuticals position peaked at $3K in Q1 2019.
  • 196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2019.

Based on Legacy Financial Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.